Lionco Pharmaceutical Group Co., Ltd. Class A

Lionco Pharmaceutical Group Co., Ltd. Class A

SSSE:603669
4.77
CNY
-0.22
(-4.41%)
-0.18EPS
4.51BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.93
1.08
0.86
0.67
1.4
2.35
2.27
1.38
1.01
0.4
0.27
0.52
0.45
0.57
Basic EPS, GAAP
0.22
0.28
0.23
0.22
0.22
0.26
0.28
0.22
0.09
-0.27
-0.21
-0.18
-0.27
-0.18
Free Cash Flow per Basic Share
0.11
0.12
0.04
0.13
0.14
0.02
0.31
0.09
0.1
-0.15
-0.08
-0.16
-0.19
- -
Dividend per Share
- -
0.24
0.17
0.15
0.04
0.15
0.39
0.16
0.22
0.11
0.01
0.01
0.01
- -
Book Value per Share
0.66
0.7
1.57
1.64
1.82
1.93
1.84
2.07
2.02
1.57
1.29
1.07
0.86
0.92
Tangible Book Value per Share
0.6
0.61
1.5
1.57
1.76
1.86
1.77
1.93
1.85
1.41
1.14
0.93
0.73
0.79
Basic Weighted Avg Shares
534
534
642
716
717
711
720
728
732
725
721
726
716
708
Sales/Revenue/Turnover
494
576
551
479
1,005
1,669
1,635
1,001
740
289
197
380
322
401
Operating Margin (%)
26.12
28.53
29.11
23.38
16.78
11.78
13.65
19.18
8.74
-57.46
-59.09
-17.65
-28.92
-4.01
Depreciation Expense
12
24
24
27
30
30
36
38
43
45
46
36
33
- -
Net Income, GAAP
115
150
150
154
161
183
202
160
66
-196
-151
-131
-193
-127
Effective Tax Rate (%)
24.97
19.01
15.24
13.12
10.6
10.52
9.57
10.7
6.49
- -
- -
- -
- -
- -
Profit Margin (%)
23.23
26
27.19
32.16
16.02
10.94
12.33
15.99
8.9
-67.71
-76.97
-34.43
-59.92
-31.66
Working Capital
54
16
737
732
792
822
825
1,303
1,139
830
638
367
47
117
LT Debt
- -
- -
- -
- -
- -
175
190
515
401
414
445
262
2
19
Total Equity
351
374
1,120
1,169
1,299
1,378
1,314
1,480
1,459
1,135
931
770
620
652
Return on Invested Capital (%)
31.2
34.75
18.43
9.4
12.94
11.96
11.88
7.72
2.66
- -
- -
- -
- -
- -
Return on Capital (%)
39.1
41.37
19.92
13.2
13.04
12.02
12.82
8.21
3.23
- -
- -
- -
- -
- -
Return on Common Equity (%)
39.1
41.33
20.04
13.45
13.04
13.65
14.98
11.46
4.49
-15.1
-14.67
-15.38
-27.8
-18.31

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
297
302
308
LT Borrowings
18
17
17
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
721
712
712
Market Capitalization
3,318
4,039
4,509

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
542
557
588
Cash, Cash Equivalents & STI
157
165
157
Accounts Receivable, Net
283
292
327
Inventories
77
76
71
Total Current Liabilities
473
458
471
Payables & Accruals
- -
- -
- -
ST Debt
297
302
308
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.87%
-15.66%
-19.42%
Free Cash Flow
165.15%
-33.85%
13.21%
Net Income, GAAP
-43.39%
-88.91%
47.78%
Sales/Revenue/Turnover
8.11%
-8.21%
-15.09%
Total Cash Common Dividend
15.42%
-22.55%
15.03%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
77
65
90
149
380
2025
50
121
- -
41
322
2026
87
171
103
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.03
-0.01
-0.12
-0.18
2025
-0.03
-0.02
- -
-0.23
-0.27
2026
- -
0.03
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

CEO
Ling Ping Tao
Full Time Employees
284
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 20, National Highway 349 Shannan Xizang Province China 856100
IPO Date
May 19, 2015
Business
Lionco Pharmaceutical Group Co., Ltd., along with its affiliates, focuses on the research, development, manufacturing, and distribution of pharmaceutical products within China. The company's diverse portfolio includes specialized categories such as parenteral nutrition agents, anti-infective medications, and digestive system drugs. Furthermore, it offers products spanning cardiovascular, antiviral, detoxification, and anti-tumor applications. The Group operates numerous research facilities dedicated to advancing chemical compounds, natural remedies, and biological medicines. Founded in 2003, Lionco Pharmaceutical Group Co., Ltd. is based in Shannan, China, and maintains a significant presence in the domestic market, recognized for its high-tech capabilities and robust growth in the pharmaceutical sector.